Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cuvitru in PIDD
NCT01218438Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2013
- Primary completion
- Mar 2015
- Modality
- Biologic
- Countries
- 2
01
Overview
A Phase 3 trial of polyvalent human immunoglobulin in primary immunodeficiency disease (PID), sponsored by Takeda. Started Jan 2013; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT01218438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01218438.